AA
EWTX icon

AlphaCentric Advisors’s Edgewise Therapeutics EWTX Stock Holding History

AlphaCentric Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$492K Buy
15,615
+912
+6% +$26.3K 0.49% 63
2025
Q4 		$365K Buy
+14,703
New +$295K 0.36% 89
2024
Q4 		$275K Buy
+10,316
New +$328K 0.27% 91

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AlphaCentric Advisors's EWTX Position: Q1 2026 in Review

AlphaCentric Advisors increased its Edgewise Therapeutics (EWTX) stake by 6.2% in Q1 2026, buying an estimated $26.3K and bringing the position to 15,615 shares worth $492K. The position accounts for 0.49% of the portfolio, ranked #63.

AlphaCentric Advisors first reported a position in EWTX in Q4 2024 and has held it in 3 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • AlphaCentric Advisors held 15,615 shares of Edgewise Therapeutics worth $492K as of Q1 2026.
  • AlphaCentric Advisors bought 912 Edgewise Therapeutics shares in Q1 2026, an estimated $26.3K.
  • Edgewise Therapeutics made up 0.49% of AlphaCentric Advisors's portfolio in Q1 2026, its #63 holding.
  • AlphaCentric Advisors first reported a position in Edgewise Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.